LA JOLLA, Calif. and JUPITER, Fla., April 14, 2014 /PRNewswire-USNewswire/ -- The Scripps Research Institute (TSRI) today announced the formation of Scripps Advance, a new drug discovery initiative to translate early-stage biomedical research projects, both internal and external to TSRI, into clinical development candidates.
Scripps Advance's first collaborator in this new endeavor is the Johnson & Johnson Innovation Center in California.
"Scripps Advance is a truly novel type of relationship designed to combine the diversity and innovation of academic research enterprises with the expertise, infrastructure and capital of the private sector," said Scott Forrest, Ph.D., TSRI's vice president of business development. "We believe this collaboration structure will prove uniquely effective. Advance will look both inside and outside of TSRI for projects to take forward and it will work with pharma companies to select and fund those projects. Johnson & Johnson Innovation is committed to innovative science, which only raises our level of excitement about Advance."
Johnson & Johnson Innovation Center in California will tap into Scripps Advance's strong ties with academic researchers at TSRI, other academic centers and early stage companies to help identify potential collaborators. As part of the relationship, Advance will facilitate match-making between Johnson & Johnson Innovation and emerging life science companies, companies-in-planning, researchers conducting translational research and entrepreneurs that are part of Scripps Advance's network.
Scripps Advance has already been active in the biotech space, collaborating with Atlas Venture, an early stage investment firm, to launch a company called Padlock Therapeutics. Padlock discovers novel therapeutics targeting the protein arginine deiminases (PADs), an emerging class of enzymes with roles in autoimmunity and epigenetic control. Padlock's technology was developed in the laboratories of TSRI investigators Paul Thompson, Ph.D., and Kerri Mowen, Ph.D., in collaboration with the Scripps Florida's high-throughput screening facility.
Todd Huffman, Ph.D., TSRI's director of drug discovery partnerships, said, "In building Scripps Advance we recognized the need to focus on therapeutic developments with the potential to lead to game changing ways in which we treat disease. The expertise and technical breadth found at our Florida site has already had a significant impact on putting drug candidates into the clinic. We look forward to broadening our footprint in this area through collaborations with Johnson & Johnson Innovation and other companies."
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information about TSRI, see www.scripps.edu. For more information about Scripps Advance, see www.scrippsadvance.com.
SOURCE The Scripps Research Institute